Creating Personalized Medicines

For two decades, PMC has tracked the growing number of personalized medicines coming to the market. The Coalition’s latest research shows that personalized medicines, meaning those whose labels reference biomarker-based targeting strategies, accounted for at least 25 percent of new U.S. Food and Drug Administration-approved drugs for each of the last eight years, up from next to none 20 years ago.

But economic and political landscapes have begun to shift, raising questions about the extent to which future market dynamics will continue to incentivize the development of personalized medicines that two-thirds of Americans say they prefer over one-size-fits-all therapies.

In this context, four biopharmaceutical industry executives will discuss their views on the future of personalized medicine, including gene and cell-based therapies, in today’s drug development environment.

During this discussion, PhRMA Vice President for Policy and Research Randy Burkholder will engage the panelists in a wide-ranging conversation about the scientific, business, and public policy-based factors that could impact the industry’s plans to develop personalized medicines in the future.

  • Moderator

    Randy Burkholder
    Vice President, Policy and Research, PhRMA

  • Panelist

    Gabriele Allegri
    Global Commercial Head, Precision Medicine, The Janssen Pharmaceutical Companies of Johnson & Johnson

  • Panelist

    Sarah Hersey
    Vice President, Precision Medicine, Bristol Myers Squibb

  • Panelist

    Steffan Ho, M.D., Ph.D.
    Vice President, Head of Translational Oncology and Oncology Diagnostics, Pfizer

  • Panelist

    Tamar Thompson
    Vice President, Head of Corporate Affairs, Alexion/AstraZeneca Rare Disease